Among them, intravenous administration was an independent modifiable risk factor, while underlying liver disease (especially liver cirrhosis), diabetes, transplant status (particularly hematopoietic stem cell transplantation), and baseline elevated urea levels as unmodifiable risk factors (elevated CRP and TG levels for cholestatic injury) provide important basis for the identification of high-risk groups and the optimization of treatment regimens. This evidence concerns the gene CRP and cirrhosis of liver.